Rapport Therapeutics, Inc. Common Stock

Rapport Therapeutics is a clinical-stage pharmaceutical company focused on the discovery and development of small molecule therapeutics for the treatment of neurological disorders. The company's pipeline is centered on precision neuromodulators, aiming to selectively target specific neuronal receptor subtypes to address underlying causes of disease with fewer off-target effects. As a pre-commercial entity, Rapport currently generates no revenue, relying on capital raises to fund its research and development initiatives.

Reviewing the company's financials, Rapport Therapeutics reported net losses of -78.3 million in 2024 and -111.5 million in 2025, with no revenue generated in either period. Free cash flow was similarly negative, standing at -67.2 million in 2024 and further deteriorating to -88.1 million in 2025, indicating significant cash burn from operations. The company held cash balances of 56.8 million in 2024 and 52.6 million in 2025, with no reported debt.

A key strength for Rapport lies in its specialized approach to neurological drug discovery, potentially offering differentiated therapies in a high-need area. However, the primary risk is typical of clinical-stage biotechs: the lengthy, costly, and uncertain path to regulatory approval and commercialization. Investors will be closely watching the progress of its lead drug candidates through clinical trials, particularly the achievement of key developmental milestones and the preservation of its cash reserves to fund ongoing operations.